HRMY
Harmony Biosciences Holdings, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Harmony Biosciences (HRMY) Stock: Buy, Sell, or Hold?
$33.55
-0.23 (-0.68%)
▼
5d:
-9.37%
30d:
-12.24%
90d:
-15.64%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect HRMY Gains
Updated Nov 10, 12:00 AM ET
QUANTITATIVE VERDICT
HOLD
MODERATE Confidence (80%)
Quality Score
60/100
Position
OVERSOLD
30-Day Fair Range
$36.93 – $39.64
Position: OVERSOLD
Forward P/E & Valuation
5.5x
FAIR
vs 5.9x historical avg
Wall Street Target
$48.08
+43.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$32.27 / $39.20
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: HRMY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Get Alerted When HRMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$69.66
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$43.26
22.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HRMY is currently trading at $33.55, which is considered oversold relative to its 30-day fair value range of $36.93 to $39.64. The stock's valuation (Forward PE: 5.5) is in line with its historical norms (5.9). Remarkably, the market is currently pricing in an annual earnings decline of 1.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HRMY is in a uptrend. Immediate support is located at $32.27, while resistance sits at $39.20.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $48.08 (+43.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HRMY is in a uptrend. Immediate support is located at $32.27, while resistance sits at $39.20.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $48.08 (+43.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$36.93 -
$39.64
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Trading Range & Key Levels
30-Day Trading Range
$36.93 -
$39.64
Current vs Trading Range
OVERSOLD
Support Level
$32.27
Resistance Level
$39.20
Current Trend
Uptrend
Technical data as of
Nov 10, 2026
Protect Your Profits
Holding HRMY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.3% below Wall St target ($48.08)
- NEUTRAL: Bottoming setup forming (57/100) — watch for confirmation
- CAUTION: 5-day price weakness (-9.4%) - monitor closely
Fundamental Context
Forward P/E (Next Year Est.)
5.53
Wall Street Target
$48.08
(+43.3%)
Revenue Growth (YoY)
12.3%
Earnings Growth (YoY)
-6.9%
Profit Margin
18.1%
Valuation Discount vs History
-1.9% cheaper
PE vs Historical
5.5 vs 5.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.9%
(market-implied from PE analysis)
1-Year Target
$32.91
(-2%)
2-Year Target
$32.29
(-4%)
3-Year Target
$31.67
(-6%)
3-Yr Target (if PE normalizes)
(PE: 6→6)
$33.77
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 27.3%)
$248.63
(+641%)
Base:
(SPY PE: 5.5, Growth: 27.3%)
$69.27
(+107%)
Bear:
(PE: 4.7, Growth: 27.3%)
$58.88
(+76%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 11.19 | Current EPS (TTM): $3.02
Bull Case
$74.32
(+122%)
Analyst growth 100.0%, PE expands to 12.3
Base Case
$67.56
(+101%)
Market implied 100.0%, PE stable at 11.2
Bear Case
$22.97
(-32%)
Severe decline -20.0%, PE contracts to 9.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.5 to 5.9
Stabilization Target:
$35.77
(+6.6%)
PE Expansion Potential:
+6.6%
Share HRMY Analysis
Share this live HRMY analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (HRMY)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Aug 4, 2026
Daily AI digest
AI Retail Discussion Summary:
Indivior Pharmaceuticals ($HRMY) announced a merger with Supernus Pharmaceuticals, beat Q2 earnings and revenue estimates, and raised its '26 outlook. The combined company is expected to generate $2.2B in annual revenues and achieve $125M in cost synergies.
Key Retail Themes:
merger announcement
earnings beat
pipeline focus
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:34 AM ET
Data refreshes hourly during market hours. Next update: 9:34 AM
Data refreshes hourly during market hours. Next update: 9:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRMY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$91 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 60 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 53 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 43 HOLD |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$64 | 58 HOLD |
Advanced HRMY Option Strategies
Professional options setups generated by AI based on today's HRMY price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive HRMY Research Pages
